In the TAK-861-2001 Phase IIb study, oveporexton significantly improved wakefulness, daytime sleepiness, and cataplexy ...

In this video interview, Michael Liu, medical student and researcher at Harvard Medical School, highlights key findings from a recent breakdown of funding cuts and how they are impacting research ...

In the Phase II LUMINOSITY study, Emrelis (telisotuzumab vedotin-tllv), a first-in-class c-Met-directed antibody-drug ...

In this video interview, Michael Liu, medical student and researcher at Harvard Medical School, discusses a recent study he conducted on the characterization of research funding cuts.

Merck’s Phase III KEYNOTE-B96 trial shows significant overall and progression-free survival gains with Keytruda plus ...

Upping the Migraine Intelligence Quotient: RWD sheds light on prevalence rates, providers and treatment variation ...

Upping the Migraine Intelligence Quotient: RWD sheds light on prevalence rates, providers and treatment variation ...

In February, the National Institutes of Health (NIH) announced a cut of “indirect expenses” in its funding for research ...

Decision follows underwhelming Phase II results from GALAXIES Lung-201 and H&N-202 trials, prompting iTeos and GSK to end ...

The Tufts Center for the Study of Drug Development (Tufts CSDD) is conducting new research aimed at understanding how study ...